The new Singapore-UK regulatory corridor allows companies to work with both countries simultaneously

Singapore and the United Kingdom have launched a new joint regulatory corridor to speed up the delivery of innovative health technologies to patients. This initiative could make cross-border development easier for small and medium-sized enterprises (SMEs) operating in Singapore.

Called the UK-Singapore Regulatory Innovation Corridor, the program allows companies to interact with both regulators simultaneously and seek early, informal joint advice in the initial stages of product development.

Regulators say the corridor aims to address a common challenge faced by healthtech and biotech companies: managing multiple regulatory systems separately and often repeating the same discussions, evidence gathering, and planning. With this new corridor, both countries hope to reduce duplication, improve clinical trial design, and prevent unnecessary delays–without compromising safety standards.

The initiative will focus on companies working in high-impact and complex areas where regulation is most challenging, including cancer, neurodegenerative diseases like dementia, obesity, rare diseases, and advanced diagnostics.

SMEs based in Singapore will find it easier to operate across both markets. Early engagement with regulators is expected to help companies plan trials more efficiently, minimize late-stage redesigns, and move more smoothly toward approval in two major life sciences hubs.

The program will kick off with Flagship Pioneering, a global life sciences investment group with biotechnology companies in both the UK and Singapore, participating in a pilot phase. If successful, the corridor may later expand to include additional companies.